Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Safety, Immunogenicity, and Efficacy Against Plasmodium Falciparum Malaria of PfSPZ Vaccine in Children in Mali

NCT04940130 is registered in ClinicalTrials.gov with Sanaria Inc. as lead sponsor.

NCT NCT04940130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04940130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Safety, Immunogenicity, and Efficacy Against Plasmodium Falciparum Malaria of PfSPZ Vaccine in Children in Mali
Lead sponsor
Sanaria Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2022
Completion date
December 10, 2022
Enrollment
290 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, malaria,falciparum